Boston Scientific Corp (BSX) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.057x

Based on the latest financial reports, Boston Scientific Corp (BSX) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.34 Billion) by net assets ($23.63 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Boston Scientific Corp - Cash Flow Conversion Efficiency Trend (1991–2024)

This chart illustrates how Boston Scientific Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Boston Scientific Corp debt and liabilities for a breakdown of total debt and financial obligations.

Boston Scientific Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Boston Scientific Corp ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
ING Group NV ADR
NYSE:ING
0.206x
Brookfield Asset Management Inc
NYSE:BAM
0.072x
Eoptolink Technology Inc Ltd
SHE:300502
0.254x
The Bank of New York Mellon Corporation
NYSE:BK
0.116x
Barclays PLC
MX:BCSN
N/A
BYD Co Ltd Class A
SHE:002594
0.076x
Emerson Electric Company
NYSE:EMR
0.034x
ADVANTEST ADR NEW/1 O.N.
F:VANA
N/A

Annual Cash Flow Conversion Efficiency for Boston Scientific Corp (1991–2024)

The table below shows the annual cash flow conversion efficiency of Boston Scientific Corp from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see Boston Scientific Corp (BSX) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $22.00 Billion $3.44 Billion 0.156x +21.81%
2023-12-31 $19.53 Billion $2.50 Billion 0.128x +47.60%
2022-12-31 $17.57 Billion $1.53 Billion 0.087x -22.81%
2021-12-31 $16.62 Billion $1.87 Billion 0.112x +14.34%
2020-12-31 $15.33 Billion $1.51 Billion 0.098x -25.64%
2019-12-31 $13.88 Billion $1.84 Billion 0.132x +272.38%
2018-12-31 $8.72 Billion $310.00 Million 0.036x -82.53%
2017-12-31 $7.01 Billion $1.43 Billion 0.203x +40.89%
2016-12-31 $6.73 Billion $972.00 Million 0.144x +52.06%
2015-12-31 $6.32 Billion $600.00 Million 0.095x -48.81%
2014-12-31 $6.84 Billion $1.27 Billion 0.185x +12.07%
2013-12-31 $6.54 Billion $1.08 Billion 0.165x -9.78%
2012-12-31 $6.87 Billion $1.26 Billion 0.183x +106.57%
2011-12-31 $11.35 Billion $1.01 Billion 0.089x +208.60%
2010-12-31 $11.30 Billion $325.00 Million 0.029x -57.61%
2009-12-31 $12.30 Billion $835.00 Million 0.068x -26.66%
2008-12-31 $13.14 Billion $1.22 Billion 0.093x +49.61%
2007-12-31 $15.10 Billion $934.00 Million 0.062x -48.70%
2006-12-31 $15.30 Billion $1.84 Billion 0.121x -42.81%
2005-12-31 $4.28 Billion $903.00 Million 0.211x -52.95%
2004-12-31 $4.03 Billion $1.80 Billion 0.448x +62.99%
2003-12-31 $2.86 Billion $787.00 Million 0.275x -7.83%
2002-12-31 $2.47 Billion $736.00 Million 0.298x +22.68%
2001-12-31 $2.02 Billion $490.00 Million 0.243x -36.33%
2000-12-31 $1.94 Billion $739.00 Million 0.382x -9.43%
1999-12-31 $1.72 Billion $727.00 Million 0.422x +33.95%
1998-12-31 $821.10 Million $258.50 Million 0.315x +285.69%
1997-12-31 $986.20 Million $80.50 Million 0.082x -44.31%
1996-12-31 $916.30 Million $134.30 Million 0.147x +341.46%
1995-12-31 $753.00 Million $25.00 Million 0.033x -83.35%
1994-12-31 $340.00 Million $67.80 Million 0.199x -25.24%
1993-12-31 $246.70 Million $65.80 Million 0.267x +56.33%
1992-12-31 $249.10 Million $42.50 Million 0.171x -47.95%
1991-12-31 $90.30 Million $29.60 Million 0.328x --

About Boston Scientific Corp

NYSE:BSX USA Medical Devices
Market Cap
$79.98 Billion
Market Cap Rank
#322 Global
#162 in USA
Share Price
$53.93
Change (1 day)
-4.67%
52-Week Range
$53.93 - $108.14
All Time High
$108.14
About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, dire… Read more